A Phase IB Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer.

Trial Profile

A Phase IB Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors OSI Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2012 Actual patient number (19) and lead trial centre added as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top